替罗非班干预对非ST段抬高急性冠脉综合征患者介入术后再灌注及心功能的影响

Effect of Tirofiban on Reperfusion and Heart Function after Percataneous Coronary Intervention in Patients with Non-ST Elevation Acute Coronary Syndrome

目的:观察使用国产替罗非班干预对非ST段抬高ACS患者介入术后再灌注及心功能的影响。方法:选择首次因非ST段抬高ACS住院的患者79例,于入院48小时内行PCI治疗,替罗非班组38例,对照组41例。所有患者于PCI术后行心肌呈色显分级判定,在发病就诊时,PCI后第7天及6个月时行超声心动图检查,并记录住院期间及随访6个月主要临床心脏事件。结果:患者临床资料及冠状动脉造影结果无统计学差异(P>0.05);替罗非班组发生心肌无再灌注情况明显低于对照组(P<0.05);两组患者PCI术前,术后第7天,术后6个月LVEF无统计学差异,但替罗非班组PCI术后LVEF恢复好于对照组;替罗非班组住院期间及术后6个月主要心脏事件发生率较低(P>0.05)。结论:在非ST段抬高ACS行PCI治疗时应用替罗非班,可明显改善心肌再灌注,减少无复流的发生,同时改善PCI术后患者心功能,减少住院期间及术后6个月主要心脏事件发生率。

Objective： To screen the effection of tirofiban on reperfusion and heart function after percataneous coronary intervention（PCI） in patients with non-ST elevation acute coronary syndrome. Methods： The study population consisted of 79 patients with non-ST elevation acute coronary syndrome, PCI undertaken in all patients within admission 48 hours, that were designed into two groups according to tirofiban used or not： tirofiban group （38 cases） and control group （41 cases） , Myocardial blush grade （MBG）were survey. 2-dimensional echocardiography were survey at base line and seventh-day, 6-month after PCI in two groups, cardiac events were to observe. Results： The baseline clinical and angiographic was similar in two groups（P〉0.05） ;no-reperfusion in tirofiban group significantly lower than control group （P〈0.05） ;and LVEF higher in tirofihan group after PCI（P〉0.05） ; but cardiac events rate lower than control group （P〉0.05）. Conclusion： In patients with non-ST elevation acute coronary syndrome, tirofiban may improve reperfusion and heart function, reduce cardiac events rate after PCI.